Auxin-induced SCFTIR1-Aux/IAA interaction involves stable modification of the SCFTIR1 complex by Leyser, O. & Kepinski, S.
Auxin-induced SCFTIR1–AuxIAA interaction involves
stable modification of the SCFTIR1 complex
Stefan Kepinski and Ottoline Leyser*
Department of Biology, University of York, Box 373, York YO10 5YW, United Kingdom
Edited by Christopher R. Somerville, Carnegie Institution of Washington, Stanford, CA, and approved July 6, 2004 (received for review April 26, 2004)
The plant hormone auxin can regulate gene expression by desta-
bilizing members of the AuxIAA family of transcriptional repres-
sors. Auxin-induced AuxIAA degradation requires the protein-
ubiquitin ligase SCFTIR1, with auxin acting to enhance the
interaction between the AuxIAAs and SCFTIR1. SKP1, Cullin, and an
F-box-containing protein (SCF)-mediated degradation is an impor-
tant component of many eukaryotic signaling pathways. In all
known cases to date, the interaction between the targets and their
cognate SCFs is regulated by signal-induced modification of the
target. The mechanism by which auxin promotes the interaction
between SCFTIR1 and AuxIAAs is not understood, but current
hypotheses propose auxin-induced phosphorylation, hydroxyla-
tion, or proline isomerization of the AuxIAAs. We found no
evidence to support these hypotheses or indeed that auxin induces
any stable modification of AuxIAAs to increase their affinity for
SCFTIR1. Instead, we present data suggesting that auxin promotes
the SCFTIR1–AuxIAA interaction by affecting the SCF component,
TIR1, or proteins tightly associated with it.
The hormone auxin influences nearly every aspect of plantgrowth, from patterning in the early embryo to the control
of adult plant architecture (1). These diverse effects are medi-
ated partly by the ability of auxin to regulate the expression of
numerous genes by controlling the abundance of transcriptional
repressor proteins of the AuxIAA family (2–5).
AuxIAA proteins, of which there are 29 in Arabidopsis, are
characterized by four conserved domains named I–IV (6, 7). A
very early biochemical manifestation of the auxin response (5
min) is the dose-dependent increase in the interaction between
AuxIAAs and the E3 ubiquitin-protein ligase SCFTIR1, as
monitored by pull-down assays in cell-free extracts (2).
SKP1, Cullin, and F-box-containing proteins (SCFs) act to
ubiquitinate their targets, marking them for degradation by the
26S proteasome (reviewed in ref. 8). They are multisubunit
enzymes named after their first three characterized subunits;
SKP1, Cullin, and an F-box-containing protein (8). The Cullin
interacts with a fourth subunit, RBX1, to catalyze ubiquitination
(8). The SKP1 protein acts as a scaffold to link the Cullin-RBX
dimer to the F-box protein. F-box proteins are characterized by
an N-terminal F-box motif through which they interact with
SKP1. Their C termini include one of a diverse range of
protein–protein-interaction domains, which confer substrate
specificity to the SCF complex (8). In the case of SCFTIR1, the
TIR1 F-box protein contains leucine-rich repeats (9), which are
required to destabilize the AuxIAAs (2).
Domain II of the AuxIAA is the site of the destabilization
signal required for interaction with SCFTIR1 (10–12). A 13-aa
core region of domain II has been shown to be necessary and
sufficient to confer auxin-regulated SCFTIR1 interaction and
instability on translationally fused reporter proteins and hence
constitutes a degron (11). Of the degron consensus sequence
(QVVGWPPVRSYRK), the central GWPPV residues are ab-
solutely essential to both fusion-protein instability and interac-
tion with SCFTIR1 (11). Mutations in this core region result in
increased and auxin-resistant AuxIAA stability, reduced
SCFTIR1 interaction, and, in the context of an otherwise intact
AuxIAA in planta, a plethora of auxin-response phenotypes (2,
7, 13). Thus, the ability of auxin to regulate plant development
depends on its ability to regulate the interaction between
AuxIAA domain II and SCFTIR1. Unfortunately, the mech-
anism by which auxin influences this interaction is poorly
understood.
Several models have been proposed to account for the effect
of auxin. Foremost has been the idea that the auxin-enhanced
AuxIAA–SCFTIR1 interaction requires covalent modification of
domain II. Most of the characterized canonical SCF–target
protein interactions from yeast and mammals depend on the
phosphorylation of the target protein (8). However, several lines
of evidence suggest that phosphorylation does not play a role in
regulating the SCFTIR1–AuxIAA interaction: The 13-aa de-
gron, necessary and sufficient for auxin-induced destabilization
of AuxIAAs, does not contain any essential phosphorylatable
residues (11), and a broad spectrum of kinase and phosphatase
inhibitors does not interfere with the interaction (13, 14). There
are a few known exceptions to the phosphorylation paradigm.
For example, the human SCFFbx2 has been shown to recognize
N-glycosylated proteins rejected by the endoplasmic reticulum
(15). A second exception is in the degradation of the transcrip-
tion factor hypoxia-inducible factor  (HIF) by von Hippel–
Lindau tumor suppressor complex, an E3 ligase structurally and
functionally analogous to the SCF (16, 17). Here interaction
depends on proline hydroxylation. This is an attractive hypoth-
esis for regulating the AuxIAA–SCFTIR1 interaction, because
the degron contains two adjacent central proline residues that
are essential for the auxin-regulated AuxIAA–SCFTIR1 inter-
action (2). However, a variety of inhibitors and enhancers of
proline hydroxylation, known to affect the stability of HIF,
have no effect on SCFTIR1–AuxIAA interaction or AuxIAA
stability in planta (13, 14). Furthermore, a synthetic proline-
hydroxylated domain II peptide was shown to interact in an
auxin-regulated manner with SCFTIR1 (14).
An alternative model is that auxin regulates the AuxIAA–
SCFTIR1 interaction by altering the isomerization state of the
domain II prolines. This hypothesis is supported by the obser-
vation that juglone, an inhibitor of the parvulin class of peptidyl
proline isomerases (PPIases) is able to inhibit the AuxIAA–
SCFTIR1 interaction (13, 14). An additional hypothetical link to
a role for proline isomerization has come from the recent
identification and characterization of the SIR1 gene, mutation in
which results in resistance to sirtinol, a synthetic compound that
was shown to destabilize AuxIAA proteins (18). SIR1 encodes
a protein with a C-terminal rhodanese-like domain that shares
homology with the C-terminal domain of a single member of the
Arabidopsis parvulin PPIase family. It has been suggested that
these two proteins might cooperate to regulate the isomerization
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of domain II prolines and hence the ability of AuxIAAs to
interact with SCFTIR1 (18).
To date, these various hypotheses about the mode of auxin
action in increasing the AuxIAA–SCFTIR1 interaction are
largely derived from predicting a specific domain II modification
and then testing for the effects of this modification or its
predicted inhibitors on the interaction. We have taken more
generic approaches to look for domain II modifications. We are
unable to find any evidence to support the idea that auxin causes
the modification of AuxIAAs to increase their affinity for
SCFTIR1. Instead, we propose that auxin acts through modifica-
tion of TIR1 or a tightly associated protein.
Methods
Plant Materials and Extracts. All transgenic and mutant lines have
been described (19). Seedlings for protein extraction were grown
at 22°C under continuous illumination for 7 days in liquid
Arabidopsis thaliana salt medium under sterile conditions (19).
Extracts were made by grinding in liquid nitrogen and solubi-
lizing in extraction buffer (0.15 M NaCl0.5% Nonidet P-400.1
M TrisHCl, pH 7.5-glycerophosphate at 10 mMPMSF
DTTNaF at 1 mM MG132 at 10 Mpepstatin A at 2 M).
Extracts were cleared by centrifugation at 18,000 g for 20 min.
Protein levels were determined by using Coomassie Plus reagent
(Pierce) according to manufacturer instructions.
Peptides and GST Fusion Proteins. The peptide biotinyl-NH-
AKAQVVGWPPVRNYRKN-COOH was synthesized by
Thermo Hybaid (Ulm, Germany). GST-AXR2 has been de-
scribed (2). To construct GST-AXR2dII, the primers 5-
AAGGATCCCTTAAAGATCCTTCTAAGCCTCC-3 and 5-
AAGAATTCTGCTGAGTCATCATGTTCTTC-3 were used
to amplify the domain II coding sequence from GST-AXR2.
This fragment was cloned in frame into pGEX-6P-1 (Amersham
Pharmacia) and transformed into BL21(DE3) Escherichia coli.
GST-AXR2dII was purified on glutathione (GSH)-Sepharose
(Amersham Pharmacia) according to manufacturer instructions.
The mutant derivative GST-AXR2dIIPP-AA was generated by
mutagenesis of the GST-AXR2dII plasmid with the QuikChange
site-directed mutagenesis kit (Stratagene) and complimentary
oligonucleotides with the sequence 5-CACAAGTGGTGG-
GATGGGCAGCTGTGAGGAACTAC-3 and expressed in
BL21(DE3) E. coli as described above.
Electrophoresis, Staining, and Western Transfer. A 1D PAGE was
performed on NuPAGE Novex 4–12% [bis(2-hydroxyethyl)ami-
no]tris(hydroxymethyl) gels (Invitrogen) according to manufac-
turer instructions. Samples run for mass-spectrometric analysis
were visualized by either Coomassie staining (SimplyBlue
SafeStain, Invitrogen) or silver staining (SilverQuest silver stain-
ing kit, Invitrogen). For Western blotting of pull-down assay
samples, 1D gels were electroblotted onto Invitrolon poly(vi-
nylidene difluoride) by using NuPAGE transfer buffer (Invitro-
gen) according to manufacturer instructions.
Mass-Spectrometric Analysis. Twelve micrograms of GST-
AXR2dII or GST-AXR2dIIPP-AA fusion protein, immobilized
on GSH-Sepharose beads (Amersham Pharmacia), was incu-
bated in 7.5 mg of crude Arabidopsis extract for 1 h at 4°C either
with or without 10 M 1-napthalene acetic acid (NAA) and then
washed five times in extraction buffer. Over several experiments
the treated fusion proteins were resolved by either 1D or 2D
SDSPAGE as described above. Protein bands or spots were
excised and destained before tryptic digestion. Bands from 1D
gels were also reduced and alkylated before digestion. These
steps and the tryptic digests were performed according to
protocols supplied with the SilverQuest silver staining kit (In-
vitrogen) except that 0.1% octyl--D-glucopyranoside was in-
cluded in the digest reaction using Promega sequencing-grade
modified trypsin. After overnight digestion, 1l of the digest was
spotted onto the matrix-assisted laser desorption ionization
(MALDI) plate and overlaid with 5 mgml1 -cyano-4-
hydroxycinnamic acid in 0.1% trif luoroacetic acid50% aceto-
nitrile. For MS analysis of domain II peptides, the peptides were
first immobilized on monomeric avidin agarose (SoftLink avidin
agarose, Promega) according to manufacturer instructions. Af-
ter treatment in plant extracts as described above, the peptides
were washed and then eluted in 2 mM biotin20 mM ammonium
acetate, pH 7.0, dried, and resuspended in 10 l of 0.1%
trif luoroacetic acid. The peptides then were concentrated on
C18 ZipTips (Millipore) and eluted in matrix solution directly
onto the MALDI plate according to manufacturer instructions.
MALDItime-of-f light (TOF) and MALDI-MSMS analyses
were performed on an Applied Biosystems 4700 proteomics
analyzer.
Pulldowns, Immunoprecipitation, Conditioning Assays, Western Blot-
ting, and Densitometry. Pulldowns with GST-AXR2dII were per-
formed as described (2). For pulldowns using the biotinylated
domain II peptide, 6.5 g of peptide was used, recovered on
streptavidin agarose (Novagen), and processed as described for
GST-based pulldowns. Immunoprecipitation of TIR1myc was
performed with anti-Myc 9E10 antibody (Covance, Berkeley,
CA) crosslinked to protein G plus agarose (Novagen) (see
Supporting Materials and Methods, which is published as sup-
porting information on the PNAS web site).
For all experiments except sirtinol treatment of intact plants,
auxin (NAA) and inhibitors were added directly to plant extracts
at the concentrations indicated. Juglone and sirtinol were pur-
chased from Calbiochem and dissolved in DMSO. The DTT
suppression of juglone was achieved by adding 2.5 mM DTT to
extracts before juglone treatment. Sirtinol treatment of intact
plants was 25 or 100 M for 3 h, both added to the growing
medium. Conditioning and partitioned inhibitor experiments
were simply elaborations of the basic pull-down assay using
similar quantities of GST fusions and domain II peptide. Thus,
for domain II conditioning experiments (see Fig. 2b), 6.5 g of
immobilized domain II peptide or 4g of GST-AXR2dII protein
were first incubated in 2.5 mg of crude tir1-1 extract (TIR1myc)
for 2 h at 4°C, then washed eight times (228 bed volumes) in a
high-saltdetergent buffer (0.5 M NaCl2% Nonidet P-400.1 M
TrisHCl, pH 7.5), and finally incubated in 2.5 mg of crude
tir1-1[TIR1myc] extract (TIR1myc) for 2 h at 4°C to assess
recovery of TIR1myc. For the partitioned jugloneN-
ethylmaleimide (NEM) experiments (see Fig. 3d), 2.5-mg ali-
quots of tir1-1 and tir1-1[TIR1myc] extract were treated with 10
M NAA and either 100 M juglone or 2.5 mM NEM. Paired
aliquots then were mixed in the presence of 2.5 mM DTT and
used for standard pull-down assays with 6.5 g of domain II
peptide. For TIR1 conditioning experiments (see Fig. 4 a and b),
TIR1myc was immunoprecipitated by using 125 l of crosslinked
anti-Myc beads per 12.5 mg of tir1-1[TIR1myc] (TIR1myc)
extract treated with or without 10 M NAA. The immunopre-
cipitates were washed eight times (640 bed volumes) in extraction
buffer and eluted by vigorous agitation in 0.5 M NaCl2%
Nonidet P-4010% dioxane0.1 M TrisHCl, pH 7.0. The eluates
were diluted 1:10 with identical aliquots of tir1-1 (TIR1myc)
extract and used in standard pull-down assays with 6.5 g of
domain II peptide.
The final processing of all pull-down assays described above
consisted of washing three times in extraction buffer and elution
in 1 lithium dodecyl sulfate loading buffer (Invitrogen), with
the eluate being collected by microcentrifugation in minispin
columns (Promega). The samples were electrophoresed and
blotted as described above. Immunodetection of TIR1myc was
performed by using a 1:1,000 dilution of monoclonal anti-c-Myc
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9E10 antibody (Covance), followed by a 1:5,000 dilution of goat
anti-mouse IgG -chain-specific peroxidase conjugate (Sigma)
and chemiluminescent detection using ECL Plus reagents (Am-
ersham Pharmacia). Densitometric measurements were made by
using a GENESNAPGENETOOLS documentation system (Syn-
Gene, Cambridge, U.K.).
Results
Auxin Does Not Induce Mass-Shifting Modifications to Domain II
Peptides. To identify any auxin-induced posttranslational modi-
fications to domain II that might regulate the interaction with
SCFTIR1, we took a mass-spectrometric approach. A transla-
tional fusion of GST and domain II of AXR2 (GST-AXR2dII),
capable of auxin-enhanced interaction with SCFTIR1, was im-
mobilized on GSH-Sepharose beads and exposed to plant extract
(initially without added auxin), washed, and resolved by SDS
PAGE. The protein then was excised and tryptically digested
before MALDITOF MS. This analysis revealed that accompa-
nying the 1,108.6-Da tryptic fragment (AQVVGWPPVR), cor-
responding to the major part of the 13-aa degron, was an
additional fragment at15.99 Da that could not be attributed to
any other part of the digested protein (Fig. 1a). Such mass shifts
are indicative of an oxidation event and, within this sequence, are
most likely the result of hydroxylation of one of the prolines. This
was confirmed by comparison of the 1,108- and 1,124-Da
MALDI MSMS spectra (data not shown) and changes in the
MALDI MS spectrum of a trypsinized GST-AXR2dII derivative
in which both prolines were substituted with alanines (GST-
AXR2dIIPP-AA), in which the 1,108- and 1,124-Da fragments
were replaced with just one of 1,056 Da (Fig. 1b). Given the
established regulation of HIF stability by proline hydroxylation
(16, 17), this was a potentially interesting result. However, the
relevance of this modification as a prerequisite for AuxIAA–
SCFTIR1 interaction is highly dubious, because the apparent
hydroxylation is not affected by auxin (Fig. 1c) and indeed is
observed, albeit at a lower level, in preparations of the bacterially
expressed GST-AXR2dII that have not been exposed to plant
extracts (data not shown). Additionally, as mentioned above, a
synthetic domain II peptide with hydroxylated prolines has been
shown to interact in an auxin-regulated manner with SCFTIR1,
and a variety of inhibitors and enhancers of proline hydroxyla-
tion, known to affect the stability of HIF in mammalian cells,
have no effect on SCFTIR1–AuxIAA interaction or AuxIAA
stability in planta (data not shown; refs. 13 and 14).
This apparent hydroxylation event was the only mass shift we
detected in these experiments. However, a region toward the
C-terminal end of the degron might be underrepresented in
our analysis because of the proximity of a number of tryptically
susceptible arginine and lysine residues. Therefore, we per-
formed similar experiments with a synthetic biotin-labeled
domain II peptide (see below) immobilized on monomeric
avidin agarose and eluted competitively with biotin. These
eluates were prepared for MALDITOF spectrometry without
electrophoresis or tryptic digestion. We found no evidence of
any modification within the domain II degron other than
proline hydroxylation.
Auxin-Enhanced SCFTIR1–AuxIAA Interaction Is Not Mediated by Sta-
ble Modification of Domain II. To monitor the AuxIAA–SCFTIR1
interaction, we previously used GST-tagged versions of the
AuxIAA proteins AXR2 and AXR3 in pull-down assays with
extracts from tir1-1 mutant plants expressing a Myc-tagged TIR1
transgene (TIR1myc) (2). In addition, we synthesized a biotin-
ylated 17-aa peptide corresponding to the core residues of
domain II and encompassing the 13-aa degron. As with GST-
AuxIAA fusions, this peptide robustly supports the auxin-
enhanced recovery of TIR1myc in pull-down assays (Fig. 2a).
To explore further whether auxin stably modifies this peptide
to enhance its interaction with SCFTIR1, we conducted a series
of conditioning experiments in which the auxin treatment of
domain II was temporally separated from its exposure to
TIR1myc. Biotinylated domain II peptide was incubated in
TIR1myc extract (tir1-1) either without or with 10 M NAA
(auxin pretreatment) for 2 h at 4°C. The peptides then were
recovered on streptavidin beads and washed extensively in a
high-saltdetergent buffer to remove auxin and dislodge bound
proteins. The domain II peptide beads were then equilibrated in
0.1 M TrisHCl, pH 7.5, and added to TIR1myc extract
(tir1-1[TIR1myc]) either without or with 10 M NAA, and the
recovery of TIR1myc in the four assays was compared. Fig. 2b
(lanes 1 and 2) shows that auxin pretreatment of the peptide had
no effect on its ability to interact with TIR1myc compared with
the mock-treated control. Additionally, Fig. 2b (lanes 3 and 4)
demonstrates that the washing regime does not affect the ability
of the peptide to interact with TIR1myc in an auxin-dependent
manner. The effectiveness of the washing after pretreatment was
judged by its ability to dislodge TIR1myc from domain II peptide
beads. Fig. 2c shows that this washing is effective, removing the
vast majority of TIR1myc. These conditioning experiments were
repeated five times with domain II peptide and three times with
GST-AXR2dII (data not shown) with identical results. Densi-
tometric quantification of five domain II peptide conditioning
experiments confirmed that there was no difference in the
recovery of TIR1myc by auxin-pretreated and mock-pretreated
peptides (t test: P 0.77). Together, these data indicate that the
domain II degron cannot be preconditioned with auxin to
interact better with TIR1. Therefore, if any auxin-induced
modification of domain II occurs, it must not only be non-mass-
Fig. 1. Auxin does not induce mass-shifting modifications within domain II.
(a and c) MALDITOF MS spectra of trypsinized GST-AXR2dII exposed to plant
extract without (a) and with (c) added auxin (10M NAA) (n5). The 1,108-Da
peak corresponding to the major part of the domain II degron and the
derivative peak at 15.99 Da are indicated. (b) MALDITOF MS spectrum of
trypsinized GST-AXR2dIIPP-AA (both prolines replaced by alanines). The new
1,056-Da peak corresponding to the major part of the mutant domain II
degron is marked. For comparison, the positions at 1,056 15.99 Da, 1,108 Da,
and 1,124 Da are indicated (n 2). n, the number of independent replicates.
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changing but also not stable or not sufficient to promote the
SCFTIR1–AuxIAA interaction.
Sirtinol Does Not Affect the SCFTIR1–AuxIAA Interaction. Because no
stable domain II modifications were induced by auxin, we next
investigated in more detail the extant evidence for a role for
proline isomerization, which could be unstable. This evidence
comes from two sources. First, the ability of plants to respond to
sirtinol, a drug that destabilizes AuxIAAs, has been shown to
require the Arabidopsis protein SIR1, which shares homology
with an Arabidopsis PPIase (18). We therefore tested whether
sirtinol could enhance the SCFTIR1–AuxIAA interaction.
Treatment with sirtinol, both of intact plants before extraction
and in the pulldown, had no effect on the interaction (Fig. 3 a
and b).
Juglone Inhibits SCFTIR1–AuxIAA Interaction Through TIR1 or Associ-
ated Proteins. The second line of evidence to support a role for
proline isomerization comes from the use of juglone, an inhibitor
of the parvulin class of PPIases, which has been shown to reduce
the SCFTIR1–AuxIAA interaction (13, 14). Juglone inhibits
parvulin-type PPIases by its covalent attachment to their cys-
teine sulfhydryl groups (20). This inhibitory effect is abolished
in the presence of modest concentrations of DTT (20). We found
this also to be true for the inhibition of SCFTIR1–AuxIAA
interaction by juglone (Fig. 3c).
The nullifying effect of DTT enabled us to perform the following
experiment to assess on which of the interacting components
juglone is acting. Aliquots of TIR1myc seedling extract (tir1-1) and
TIR1myc extract (tir1-1[TIR1myc]), equal in terms of volume and
protein concentration, were used. In the first treatment (Fig. 3d,
lane 1), one aliquot of TIR1myc extract was treated with 10 M
NAA and 100 M juglone, and one aliquot of TIR1myc extract
was treated with 10 M NAA alone. Both aliquots were incubated
for 1 h at 4°C. The two aliquots then were combined in the presence
Fig. 2. Auxin-enhanced SCFTIR1–AuxIAA interaction is not mediated by
stable modification of the AuxIAA. (a) A synthetic AuxIAA domain II peptide
was used in pull-down assays from extracts of tir1-1[TIR1myc] plants without
and with auxin (10 M NAA) added in vitro. The recovery of TIR1myc on
domain II peptide beads was assessed by immunoblotting with anti-c-Myc
antibody (n  40). (b) Immobilized domain II peptides were mock-treated or
auxin-treated in TIR1mycextract before being washed and used in pull-down
assays from TIR1myc extract either mock- or auxin-treated as indicated in the
schematic. The products were immunoblotted with anti-c-Myc antibody (n
5). (c) The effect of high-saltdetergent washing of otherwise identical pull-
downs (n 1). n, the number of independent replicate, *, the position of the
TIR1myc band.
Fig. 3. The inhibitors juglone and NEM but not sirtinol affect SCFTIR1–Aux
IAA interaction. (a) Standard domain II peptide pulldowns from extracts of
tir1-1[TIR1myc] plants mock-treated or treated with sirtinol for 3 h before
extraction (n2). (b) As described for a but with 100M sirtinol added directly
to the pull-down assay (n  2). (c) Standard domain II peptide pulldowns
treated with 200 M juglone andor 2.5 mM DTT (n  4). (d) Partitioned
jugloneNEM experiment. Each lane represents a pulldown from an aliquot of
TIR1myc extract combined with an aliquot of TIR1myc extract. Before being
mixed in the presence of DTT, the aliquots were pretreated with juglone or
NEM or were mock-treated as indicated in the schematic (n 3). (e) Standard
domain II peptide pulldowns treated with 2.5 mM NEM andor 2.5 mM DTT as
indicated (n 2). (c–e) All extracts were treated with 10 M NAA in vitro. ( f)
Standard domain II peptide pulldowns treated with GSHoxidized GSH
(GSSG), diamide, and H2O2 as indicated. n, the number of independent rep-
licates; *, the position of the TIR1myc band.
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of 2.5 mM DTT and used in a pull-down assay with biotinylated
domain II peptide. The second treatment (Fig. 3d, lane 2) was the
reciprocal of the first such that both TIR1myc and TIR1myc
extracts received 10 M NAA, whereas juglone was administered
only to the TIR1myc aliquot. If parvulin-type PPIases, which
would be distributed similarly in the two extract types, were acting
to change the conformation of proline(s) within the domain II
degron, then there should be little difference in the recovery of
TIR1myc from the two treatments; comparison of lanes 1 and 2 in
Fig. 2d shows that this is not the case. The reduced interaction with
TIR1myc from the treatment in which juglone was added to the
TIR1myc aliquot is similar to that observed when juglone is added
in the standard pull-down assay (compare with Fig. 3c), which
indicates that juglone does not affect a PPIase operating on the
domain II prolines and additionally that if proline isomerization is
involved, it is of prolines in TIR1 or TIR1-associated proteins.
An alternative explanation is that the juglone adducts on the
sulfhydryls of some or all of the 23 cysteines of TIR1 simply
reduce its ability to interact with AuxIAAs. Some support for
this idea comes from our observation that the general sulfhydryl
alkylating agent, NEM, also reduces SCFTIR1–AuxIAA inter-
action (Fig. 3e). As with juglone, the inhibitory effect of NEM
is abolished in the presence of DTT (Fig. 3e). An experiment
identical to the partitioned juglone experiment but with juglone
substituted by 2.5 mM NEM shows that NEM also affects TIR1
to reduce the SCFTIR1–AuxIAA interaction (Fig. 3d, lanes 3
and 4). Although these effects of NEM and juglone may be quite
general, we also considered the possibility that cysteine sulfhy-
dryl chemistry might play a more specific role in regulating
SCFTIR1–AuxIAA interaction through redox sensing. We tested
this theory by performing pulldowns, both with and without
auxin, in the presence of 5 mM diamide (to promote disulfide
bond formation) or 50 mM H2O20.5 mM CuCl20.5 mM
ascorbate (to generate highly reactive oxygen species) and in
extracts with artificially skewed ratios of reduced GSHoxidized
GSH. The manipulation of GSHoxidized GSH ratios in either
direction had no effect, whereas the imposition of relatively
severe disulfide or reactive oxygen species stress resulted in only
a modest reduction in TIR1myc recovery in both auxin-treated
and untreated assays (Fig. 3f ). These data are not consistent with
redox regulation of SCFTIR1–AuxIAA interaction.
Auxin-Enhanced SCFTIR1–AuxIAA Interaction May Require Modifica-
tion of TIR1 or Associated Proteins. Because auxin does not seem to
affect domain II, we asked whether TIR1 could be predisposed
to better interaction with AuxIAAs by auxin treatment. This
theory was tested by comparing the interaction between domain
II peptides and TIR1myc recovered from auxin-treated and
untreated extracts: anti-c-Myc antibody was used to immuno-
precipitate TIR1myc from tir1-1[TIR1myc] extracts either mock-
treated or treated with 10 M NAA. These immunocomplexes
were washed extensively (eight times  640 bed volumes) and
eluted by vigorous agitation in 0.5 M NaCl2% Nonidet P-40
10% dioxane0.1 M TrisHCl, pH 7.0.
The eluates were diluted 1:10 with identical aliquots of tir1-1
extract (i.e., lacking TIR1myc) and used in pull-down assays with
biotinylated domain II peptide. The reconstituted TIR1myc ex-
tracts contained equivalent levels of TIR1myc (Fig. 4a, lanes 4 and
5). Comparison of lanes 1 (mock-pretreated) and 2 (auxin-
pretreated) of Fig. 4a shows that auxin pretreatment of TIR1myc
subsequently enhanced its recovery on domain II peptide beads.
To control absolutely for possible auxin carry-through from
the pretreatment, the experiment was repeated by using the
following modification. Agarose beads without antibody were
exposed to tir1-1 extract either mock-treated or treated with 10
M NAA and then processed as described above. These eluates
then were combined with the immunoprecipitated eluates such
that NAA IP eluate was added to NAA control eluate, and
NAA IP eluate was added to NAA control eluate. Each
combined eluate then was diluted 1:10 with identical aliquots of
tir1-1 extract and used in pull-down assays with biotinylated
domain II peptide (Fig. 4b). Here again, the reconstituted
extracts contained equivalent levels of TIR1myc (Fig. 4b, lanes
4 and 5), and auxin pretreatment of TIR1myc enhanced its
recovery on domain II peptide beads (Fig. 4b, lanes 1 and 2).
The recovery of TIR1myc in these experiments is much lower
than that in the standard pull-down assay, and thus the exper-
iments are on the limits of Myc detection. This is because the
reconstituted extracts contain considerably lower levels of
TIR1myc than extracts made directly from tir1-1[TIR1myc]
seedlings. Nonetheless, the increase in interaction caused by
auxin pretreatment of TIR1myc is completely reproducible.
Densitometric measurements over four experiments identical to
that shown in Fig. 4b show that TIR1myc recovery is increased
4.41-fold (0.13 SE) by auxin preconditioning of TIR1myc
complexes (Fig. 4c), which suggests that there is an auxin-
induced modification of TIR1 or TIR1-associated proteins,
Fig. 4. Auxin-enhanced SCFTIR1–AuxIAA interaction may require modifica-
tion of TIR1 or tightly associated proteins. (a) TIR1myc was immunoprecipi-
tated (IP) from either mock- or auxin-treated tir1-1[TIR1myc] extract, washed,
and eluted into tir1-1 extract. Pulldowns with domain II peptide were per-
formed in these reconstituted extracts as indicated in the schematic. (b) As
described for a but performed with additional controls for auxin carry
through: in parallel with the immunoprecipitation stages, control beads (no
antibody) were treated with and without auxin and combined with immuno-
precipitated beads just before elution (NAA IP withNAA control,NAA IP
with NAA control). (a and b) Lane 3 shows the full NAA-induced response
where 10 M NAA was added to the reconstituted extracts before pulldown.
Lanes 4–6 in show the levels of TIR1myc in reconstituted extracts made with
tir1-1 extract and NAA IP, NAA IP, and no immunoprecipitation, respec-
tively. (c) Mean densitometric measurements of mock- and NAA-pretreated
TIR1myc in pulled-down with domain II peptide as a percentage of the full
NAA-induced response (n4). n, the number of independent replicates; *, the
position of the TIR1myc band. (Error bars, SEM.)
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which facilitates enhanced interaction with AuxIAAs. Addition
of 10 M NAA to these reconstituted TIR1myc extracts further
enhanced the interaction with domain II peptide (Fig. 4 a and b,
lane 3).
Discussion
The regulation of the interaction between SCFTIR1 and Aux
IAAs is unorthodox, conforming to none of the known modes of
SCF–target interactions. A key question is whether auxin pro-
motes the modification of target AuxIAAs, increasing their
affinity for SCFTIR1. We suggest that this is not the case and that
instead the auxin-induced modification of TIR1 or tightly asso-
ciated proteins is the regulatory step determining SCFTIR1–Aux
IAA interaction.
We have taken a generic approach to identify any auxin-
regulated modifications to AuxIAA domain II that might
enhance interaction with SCFTIR1. Using MS, we could not
detect any auxin-regulated modification of tagged AuxIAA
proteins and peptides. Our search was confined to the 13-aa
degron of domain II, previously shown to be necessary and
sufficient to confer auxin-enhanced instability on a translation-
ally fused reporter protein (11). We did detect the apparent
auxin-independent hydroxylation of one of the domain II pro-
lines. Although seemingly irrelevant to the regulation of
SCFTIR1–AuxIAA interaction, this modification is puzzling,
because it seems to be specific to the degron prolines. Several
other tryptic fragments of GST-AXR2dII-containing prolines
and even tandem prolines showed no signs of hydroxylation.
Similarly, it was not possible to predispose tagged domain
II-containing proteins and peptides to interact better with TIR1
by pretreating them with auxin in plant extracts. In the first stage
of these experiments, the domain II peptidesproteins were
treated with auxin such that they could accumulate any auxin-
induced modifications to which they might be susceptible before,
and separate from, the second stage in which their ability to
interact with TIR1myc was tested. To counter the possibility that
the domain II targets might associate with endogenous TIR1-like
proteins in the first stage, preventing later interaction with
TIR1myc, a wash was performed before the second stage. As
well as efficiently removing bound proteins, this wash also
prevented the carry-over of exogenous auxin. Over the course of
several experiments, there was never the slightest hint of a
conditioning effect. Although it is possible that there are mod-
ifications to domain II peptidesproteins that are not revealed in
these experiments, because they are not stable, there is a simpler
explanation that accounts for all the data described here: that the
auxin-induced interaction between AuxIAAs and SCFTIR1 does
not depend on auxin-regulated modification of domain II. In this
model, domain II simply defines a structural module required for
the interaction of AuxIAA with SCFTIR1, with auxin acting
elsewhere to promote the association.
This model is supported further by our finding that TIR1myc
immunologically recovered from auxin-treated extracts interacts
better with domain II peptides than that recovered from extracts
not treated with auxin. This enhanced interaction with auxin
pretreatment is less than the full auxin-enhanced interaction
observed when auxin is added to extracts containing all the
components together, and indeed, addition of auxin directly to
the reconstituted extracts containing immunologically recovered
TIR1myc further increases its interaction with domain II pep-
tides (compare lanes 2 and 3 in Fig. 4 a and b). This result
suggests that the modification to TIR1myc immunocomplexes
does not fully survive the washing regime or does not persist at
basal auxin levels in the second-stage extracts or does not
represent the entire means by which auxin affects the enhance-
ment of SCFTIR1–AuxIAA interaction. In this context, it is
interesting to note that the data do not distinguish between TIR1
or a protein tightly associated with it being modified in response
to auxin or indeed a third-party protein becoming associated
with or dissociated from TIR1 as a result of the auxin treatment.
In any event, something happens to the TIR1 immunocomplexes
to make their interaction with AuxIAAs more likely and is thus
the first indication of where auxin might act to promote the
ubiquitination and destruction of AuxIAAs. The obvious ques-
tion is: What might this modification be?
Some information here can be derived from the pharmaco-
logical studies used to test for AuxIAA modification. For
example, there is now considerable literature describing how the
pharmacological inhibition of phosphorylation and dephosphor-
ylation do not affect the interaction between AuxIAAs and
SCFTIR1 (13, 14). To this we add our own finding that the kinase
inhibitors staurosporine, U0126, and genistein and the phospha-
tase inhibitors calyculin A, okadaic acid, and NaF have no effect
on the SCFTIR1–AuxIAA interaction (data not shown). Al-
though these studies do not definitively exclude a role for
phosphorylation, they certainly give no indication of its involve-
ment. Similarly, inhibitors of proline hydroxylation have no
effect on the interaction (13, 14). In contrast, treatment of TIR1
with juglone and NEM, both of which form cysteine adducts,
reduces auxin-enhanced SCFTIR1–AuxIAA interaction. Be-
cause TIR1 contains 23 cysteine residues and the interaction
seems not to involve redox regulation of cysteine sulfhydryl
chemistry, this is likely a nonspecific effect.
The destruction of proteins by signal-induced SCF-mediated
proteolysis is an important component of numerous and diverse
eukaryotic signaling pathways. It will be interesting to determine
what proportion of SCF–target interactions are regulated by
modification of the target, the SCF complex, or both.
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